Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS) has announced the initiation of a Phase 2 clinical program for its third-generation iLink™ therapy aimed at treating keratoconus. This innovative therapy utilizes a proprietary system to deliver ultraviolet light for corneal cross-linking, enhancing the strength and shape of the cornea. The Phase 2 study will involve two multi-center, randomized, controlled trials to assess customized versus non-customized treatment patterns and a new bio-activation system. Patient enrollment will occur across the United States, Europe, South America, and Asia, with a follow-up period of six months.

Glaukos Corporation (GKOS) reported its Q4 2021 net sales at $73.2 million, consistent with Q4 2020. Glaucoma and Corneal Health net sales were $57.1 million and $16.2 million, respectively. The gross margin improved to 77% from 73% a year earlier. However, the company faced a net loss of $21.9 million, or ($0.47) per diluted share, worsened from a net loss of $10.6 million in Q4 2020. For the full year, net sales increased by 31% to $294.0 million. The company projects 2022 net sales between $265 million and $275 million.

Glaukos Corporation (NYSE: GKOS) has announced key executive leadership changes effective April 1, 2022, to drive future growth. Joseph Gilliam becomes President and COO, previously CFO since May 2017. Chris Calcaterra transitions to Executive VP, Global Commercial Operations, after serving as COO since February 2017. Alex Thurman is promoted to CFO, having been VP of Finance. Tomas Navratil, Ph.D., takes on the role of Chief Development Officer, focusing on R&D. These promotions aim to align leadership with strategic objectives for transforming chronic eye disease treatments.

Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2021 financial results post-market on February 22, 2022. A conference call is scheduled for 1:30 p.m. PST (4:30 p.m. EST) the same day to discuss these results. Investors can access the live webcast via the company’s website. Glaukos specializes in innovative therapies for glaucoma and related ophthalmic disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) and launched multiple devices since 2012.

Glaukos Corporation (NYSE: GKOS) has commenced a Phase 2 clinical trial of GLK-301, targeting Dry Eye Disease (DED). This investigational drug, using Glaukos' innovative iLution platform, is formulated as a cream applied to the eyelids for transdermal delivery of pilocarpine. The trial will assess safety and efficacy across 200 patients over 28 days, followed by a safety follow-up. This development addresses a significant clinical need in the ophthalmic market, as stated by CEO Thomas Burns, emphasizing the potential of the iLution platform in treating chronic eye diseases.

Glaukos Corporation (NYSE: GKOS) has initiated the first patient enrollment in a Phase 2 clinical trial for GLK-302, targeting presbyopia treatment. This investigational drug employs the iLution platform's cream-based drug formulation for transdermal delivery via the eyelid. The trial is designed to assess safety and efficacy across three dosage levels with 120 presbyopic patients expected to participate. The company seeks to address unmet needs for effective, dropless therapies as presbyopia affects millions globally.

Glaukos Corporation (NYSE:GKOS) announced positive outcomes from its Phase 2b clinical trial of the iDose TR implant for glaucoma treatment, showing that approximately 70% of subjects maintained controlled intraocular pressure with fewer topical medications over 36 months. The trial demonstrated an average IOP reduction of 8.3 mmHg and a favorable safety profile, with no significant adverse effects reported. Following these promising results, Glaukos is preparing for a Phase 3 trial, with NDA submission targeted for 2022 and potential FDA approval in 2023.

Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iPRIME^™ Viscodelivery System, which is designed for the delivery of viscoelastic fluid during ophthalmic surgery. This sterile, single-use device represents an advancement in minimally invasive glaucoma surgery (MIGS) technology. CEO Thomas Burns highlighted the importance of this clearance in expanding Glaukos' innovative ophthalmic solutions and maintaining their leadership in the MIGS marketplace.

Glaukos Corporation (NYSE: GKOS) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET. The event will be accessible via a live and archived webcast on Glaukos' investor relations website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent devices, launched between 2012 and 2020, and offers pharmaceuticals for corneal health enhancement.